Stryker will launch its Incompass Total Ankle System at the 2025 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Savannah, Georgia, September 10–13, 2025. The FDA-cleared system is intended for patients with end-stage ankle arthritis and introduces an implant with an enhanced instrument platform.
Incompass was developed to mimic Stryker’s Infinity and Inbone with a similar implant profile, fixation and sulcus articulation. Leveraging these two legacy designs, Stryker created Incompass, aiming to advance clinical performance, address evolving surgeon needs and deliver meaningful value to hospitals and patients.
The system offers intraoperative flexibility, enabling surgeons to adjust implant configurations in real time to support patient-specific needs. Incompass includes 3D-printed porous metal tibial and talar components engineered to promote early bony ingrowth, often as early as four weeks. By combining implant options and reducing instrumentation, the system helps reduce procedural complexity, enhance decision-making and lower sterilization demands.
The implants were designed using SOMA, Stryker’s Orthopedic Modeling and Analytics tool, which analyzed real patient anatomy from arthritic ankle CT scans in the Prophecy database. SOMA was used to study bone quality and optimize implant location.
